OMB control number
Accelerated Approval Disclosures on Direct-to-Consumer Prescription Drug Websites
OMB 0910-0872 · HHS/FDA.
OMB 0910-0872
This study will examine the effect of the presence, language, and prominence of a disclosure communicating information related to a prescription drug’s accelerated approval in direct-to-consumer promotional materials. We plan to conduct one pretest (N = 385) and one main study (N = 633) not longer than 20 minutes, administered via Internet panel. We will vary the presence and prominence of the disclosure (e.g., varying the presence, size, color, and location of the disclosure) on a website for a fictitious prescription drug. Participants will view the website and then answer questions about the drug information, including the disclosure.
The latest form for Accelerated Approval Disclosures on Direct-to-Consumer Prescription Drug Websites expires 2020-06-30 and is listed under ICR 201908-0910-019.
Latest Forms, Documents, and Supporting Material
| Document | Type |
|---|---|
| Justification for No Material/Nonsubstantive Change | |
| Justification for No Material/Nonsubstantive Change | |
| Supporting Statement B | |
| Supporting Statement B | |
| Supporting Statement A | |
| Supporting Statement A | |
| Other-Study Collection Instruments |
All Historical Document Collections
| Reference | Filing | Received | Concluded | Action |
|---|---|---|---|---|
| 202211-0910-004 | No material or nonsubstantive change to a currently approved collection | 2022-11-22 | Approved without change | |
| 202204-0910-010 | Reinstatement with change of a previously approved collection | 2022-04-08 | Approved without change | |
| 201908-0910-019 | No material or nonsubstantive change to a currently approved collection | 2019-09-12 | Approved without change | |
| 201905-0910-001 | New collection (Request for a new OMB Control Number) | 2019-05-09 | Approved with change |
OMB Details
Pretesting Screener
Federal Enterprise Architecture: Health - Consumer Health and Safety